Gene Therapy for Muscular Disorders
Evvnt Promotion / evvnt
Archive
21.02.2023 - 23.02.2023 Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, USA
Time: 9:30 am to 4:30 pm
Conference themes
The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial.
The past twelve months have seen an unprecedented level of excitement, investment, and progression within the gene therapy for muscular disorders field. As the industry endeavours to move gene therapy treatment through the preclinical and clinical pipeline, in context of reducing toxicity and increasing efficacy, attending the 3rd Annual Gene Therapy for Muscular Disorders Summit has never been so crucial.
Scientific Society
Hanson Wade
Hanson Wade
Notes
Brochure: https://go.evvnt.com/1443975-3?pid=4832
Speakers: Adam Cockrell, Senior Director of Vector Biology, AavantiBio, Alex Murphy, Senior Medical Director, Roche, Beatrice Darimont, Chief Scientific Officer, Cytoo and More
Brochure: https://go.evvnt.com/1443975-3?pid=4832
Speakers: Adam Cockrell, Senior Director of Vector Biology, AavantiBio, Alex Murphy, Senior Medical Director, Roche, Beatrice Darimont, Chief Scientific Officer, Cytoo and More
Enquiries and Registration:
https://go.evvnt.com/1443975-2?pid=4832
Ms. Emily Birt
Health Services, Public Health
Languages
English
English
Congress fees
USD 2599.00 - USD 5396.00
USD 2599.00 - USD 5396.00
Participants expected
1000
1000
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."
